| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1323300 | Journal of Organometallic Chemistry | 2012 | 9 Pages |
The potential application of metallocene complexes into the cancer research was established by the pioneer work of Köpf-Maeir and Köpf in the late 1970s. The combination of organometallic chemistry and biochemistry created a new research area: bioorganometallic chemistry. Bioorganometallic chemistry has developed rapidly in the last thirty years leading to application of organometallic species into diagnostic, sensors, immunoassays and anticancer research among others. This review focuses on the bioorganometallic chemistry of molybdenocene dichloride and its derivatives as metal-based anticancer drugs. The anticancer properties of molybdenocene dichloride and its derivatives are described as well as the mechanism of action, aqueous and coordination chemistry, and molybdenocene–biomolecule interactions.
Graphical abstractThis review focuses on the bioorganometallic chemistry of molybdenocene dichloride and its derivatives as metal-based anticancer drugs. The anticancer properties of molybdenocene dichloride and its derivatives are described as well as the mechanism of action, aqueous and coordination chemistry, and molybdenocene–biomolecule interactions.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Molybdenocene dichloride anticancer agents with lower toxicity than cis-platin. ► Human serum albumin as transport protein of molybdenocene dichloride. ► Structure modification of molybdenocene dichloride yields water soluble complexes with enhanced anticancer activity. ► Molybdenocene with proliferative activity on hormone dependent breast cancer due to its estrogen-like behavior.
